Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells in vitro
- PMID: 37334930
- DOI: 10.14670/HH-18-637
Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells in vitro
Abstract
Background and aims: Eukaryotic translation initiation factor 5A2 (EIF5A2) has been reported to be involved in metastasis and chemotherapy resistance in many human cancers. However, the effect and mechanism of EIF5A2 in oral cancer cells are unknown. Here, we investigated the effects of targeting EIF5A2 on chemotherapy resistance in oral cancer cells in vitro.
Methods: By using a lentiviral system, we investigated the effects of targeting EIF5A2 on the invasion, migration, growth, and chemosensitivity of SCC-9 cells to CDDP in vitro. Through the method of gene intervention, we explore the role of pro-apoptotic Bim and epithelial and mesenchymal marker E-cadherin protein in this process and the regulation of EIF5A2 on Bim and E-cadherin.
Results: Targeting EIF5A2 reduces invasion and migration in SCC-9 cells partly through upregulation of E-cadherin expression; Targeting EIF5A2 promotes cell apoptosis and inhibits cell survival as well as increasing chemosensitivity in SCC-9 cells through upregulation of Bim expression.
Conclusion: EIF5A2 may be a novel potential therapeutic target for oral cancer by upregulation of Bim and E-cadherin.
©The Author(s) 2024. Open Access. This article is licensed under a Creative Commons CC-BY International License.
Similar articles
-
MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer.World J Gastroenterol. 2015 Aug 21;21(31):9337-47. doi: 10.3748/wjg.v21.i31.9337. World J Gastroenterol. 2015. PMID: 26309359 Free PMC article.
-
MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.J Cell Mol Med. 2019 Nov;23(11):7190-7199. doi: 10.1111/jcmm.14197. Epub 2019 Feb 23. J Cell Mol Med. 2019. PMID: 30801960 Free PMC article.
-
Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.Int J Oncol. 2020 Dec;57(6):1368-1380. doi: 10.3892/ijo.2020.5143. Epub 2020 Nov 2. Int J Oncol. 2020. PMID: 33174013 Free PMC article.
-
Roles of eukaryotic initiation factor 5A2 in human cancer.Int J Biol Sci. 2013 Oct 12;9(10):1013-20. doi: 10.7150/ijbs.7191. eCollection 2013. Int J Biol Sci. 2013. PMID: 24250246 Free PMC article. Review.
-
Unveiling EIF5A2: A multifaceted player in cellular regulation, tumorigenesis and drug resistance.Eur J Pharmacol. 2025 Jun 15;997:177596. doi: 10.1016/j.ejphar.2025.177596. Epub 2025 Apr 5. Eur J Pharmacol. 2025. PMID: 40194645 Review.
References
-
- Al-Othman M.O., Morris C.G., Hinerman R.W., Amdur R.J. and Mendenhall W.M. (2003). Distant metastases after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck 25, 629-633. - PubMed
-
- Chen Z., Yu T., Zhou B., Wei J., Fang Y., Lu J., Guo L., Chen W., Liu Z.P. and Luo J. (2016). Mg(II)-catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. Biomaterials 81, 125-134. - PubMed
-
- Chi A.C., Day T.A. and Neville B.W. (2015). Oral cavity and oropharyngeal squamous cell carcinoma: an update. CA Cancer J. Clin. 65, 401-421. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials